Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook [Yahoo! Finance]
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) had its price target raised by analysts at HC Wainwright from $3.00 to $32.00. They now have a "buy" rating on the stock.
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE